Metrochem API Private Limited Metrochem API Private Limited

X

Find Drugs in Development News & Deals for Olaparib

PharmaCompass
Related ProductsRelated Products
API SUPPLIERS
API Suppliers

API Suppliers

US DMFs Filed

US DMFs Filed

CEP/COS Certifications

CEP/COS Certifications

0

JDMFs Filed

JDMFs Filed

0

EU WC

EU WC

Listed Suppliers

Listed Suppliers

API REF. PRICE (USD / KG)
INTERMEDIATES
DOSSIERS // FDF
USA (Orange Book)

USA (Orange Book)

Europe

Europe

Canada

Canada

Australia

Australia

South Africa

South Africa

Uploaded Dossiers

Uploaded Dossiers

GLOBAL SALES (USD Million)

U.S. Medicaid

Annual Reports

EXCIPIENTS
PATENTS & EXCLUSIVITIES

USFDA Orange Book Patents

USFDA Exclusivities

DIGITAL CONTENT

Blog #PharmaFlow

News

REF STANDARD

EDQM

0

USP

0

JP

0

Other Listed Suppliers

SERVICES

0

Details:

Keytruda (pembrolizumab) is an anti-programmed death receptor-1 (PD-1) therapy, which is being evaluated in combination with Lynparza (olaparib), a PARP inhibitor for the treatment of metastatic nonsquamous non-small cell lung cancer.


Lead Product(s): Pembrolizumab,Olaparib,Pemetrexed

Therapeutic Area: Oncology Product Name: Keytruda

Highest Development Status: Phase IIIProduct Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 21, 2024

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Imfinzi (durvalumab), a PD-L1 inhibitor plus platinum-based chemotherapy followed by Imfinzi plus Lynparza (olaparib), a PARP inhibitor, demonstrated an improvement in patients with mismatch repair proficient advanced endometrial cancer compared to chemotherapy alone.


Lead Product(s): Durvalumab,Olaparib

Therapeutic Area: Oncology Product Name: Imfinzi

Highest Development Status: Phase IIIProduct Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 18, 2024

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Ibyra (olaparib) is a poly (ADP-ribose) polymerase (PARP) inhibitor, which is approved in India for the treatment of HRD-positive and BRACA-positive cancer patients.


Lead Product(s): Olaparib

Therapeutic Area: Oncology Product Name: Ibyra

Highest Development Status: ApprovedProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 13, 2024

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

TNG348 is a novel selective inhibitor of USP1 (ubiquitin-specific protease 1) which is in phase 1/2 clinical trials as a single agent and in combination with olaparib, a PARP inhibitor, in patients with BRCA1/2-mutant or other HRD+ (homologous recombination deficient) cancers.


Lead Product(s): TNG348,Olaparib

Therapeutic Area: Oncology Product Name: TNG348

Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 03, 2024

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Merck is assessing its leading product, Keytruda (pembrolizumab), an anti-PD-1 therapy, in combination with maintenance LYNPARZA, a PARP inhibitor, in Phase III clinical trials for treating patients with metastatic squamous non-small cell lung cancer.


Lead Product(s): Pembrolizumab,Olaparib

Therapeutic Area: Oncology Product Name: Keytruda

Highest Development Status: Phase IIIProduct Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable December 07, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Imfinzi (durvalumab) a PD-L1 inhibitor in combination with Lynparza (olaparib) is a first-in-class PARP inhibitor is being evaluated in phase 3 clinical trials for the treatment of advanced or recurrent endometrial cancer.


Lead Product(s): Durvalumab,Olaparib

Therapeutic Area: Oncology Product Name: Imfinzi

Highest Development Status: Phase IIIProduct Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable October 21, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

TNG348, a novel inhibitor of USP1 (ubiquitin-specific protease 1), is being developed for the treatment of BRCA1/2 mutant and other HRD+ (homologous recombination deficient) cancers.


Lead Product(s): TNG348,Olaparib

Therapeutic Area: Oncology Product Name: TNG348

Highest Development Status: IND EnablingProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable September 06, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Lynparza (olaparib) is a first-in-class PARP inhibitor and approved in combination with abiraterone for the treatment of BRCA-mutated metastatic castration-resistant prostate cancer.


Lead Product(s): Olaparib,Abiraterone Acetate,Prednisone

Therapeutic Area: Oncology Product Name: Lynparza

Highest Development Status: ApprovedProduct Type: Small molecule

Partner/Sponsor/Co